Table 1.

Mean characteristic of concentrates of von Willebrand factor/factor VIII and von Willebrand factor alone approved for the treatment of von Willebrand disease.

Product, manufacturer	Purification method	Viral Inactivation method	VWF:RCo/Ag (ratio)*	VWF:RCo/FVIII (ratio)*
Alphanate, Grifols	Heparin ligand CT	S/D + dry heat (80°C, 72 h)	0.9	1.2
Factor 8Y, Bio Products Laboratory	Heparin/glycine precipitation	Dry heat (80°C, 72 h)	0.6	1.8
Fanhdi, Grifols	Heparin ligand CT	S/D + dry heat (80°C, 72 h)	0.8	1.2
Haemate P, CSL Behring	Multiple precipitation	Pasteurization (60°C, 10 h)	0.8	2.4
Immunate, Baxalta	Ion exchange CT	S/D + vapor heat (60°C, 10 h)	0.6	0.8
Talate, Takeda	Ion exchange CT	S/D + vapor heat (60°C, 10 h)	0.5	1.1
Voncento/Biostate, CSL Behring	Multiple precipitation + albumin ligand CT	S/D + dry heat (80°C, 72 h)	0.8	2.4
Vonvendi, Takeda	Recombinant VWF, IA purification	NF	–	Negligible FVIII
Wilate, Octapharma	Ion exchange + size exclusion CT	S/D + dry heat (100°C, 72 h)	0.9–1.0	1.0
Wilfactin, LFB	Ion exchange + affinity CT	S/D + NF + dry heat (80°C, 72 h)	0.7	60

Ag, antigen; CT, chromatography; FVIII, factor VIII; IA, immune-affinity; NF, nanofiltration; RCo, ristocetin cofactor; S/D, solvent/detergent; VWF, von Willebrand factor.

^*Data derived from the WFH Online Registry of Clotting Factor Concentrates, 2018.